News
Teo Garcia-Millan, chief executive officer of CDotBio in laboratory University of Bristol, spin-out CDotBio wins prestigious Armourers & Brasiers Venture Prize ...
Moderna (MRNA) stock rises as the company's Spikevax COVID-19 vaccine gets FDA approval for kids 6 months-11 years at higher ...
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to ...
BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...
A solid-phase DNA-encoded library (DEL) was studied for binding the RNA repeat expansion r(CUG)exp, the causative agent of the most common form of adult-onset muscular dystrophy, myotonic dystrophy ...
The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...
3d
Clinical Trials Arena on MSNArrowhead doses first patient in Phase III trial of zodasiran for HoFH treatmentThe placebo-controlled study is aimed at assessing the safety and efficacy of zodasiran in adults and adolescents with HoFH.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results